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Metabolic disorders of the cardiovascular 
system, including atherosclerosis, obesity, 
diabetes, and hypertension, are the leading 
cause of morbidity and mortality in the 
western world. Metabolic syndrome is asso-
ciated with a combination of risk factors, 
including nutrient excess, hyperglycemia, 
hyperlipidemia, insulin-resistance, and obe-
sity that, when occurring together, increase 
the risk of developing cardiovascular met-
abolic disorders (CVMDs). In individu-
als with this syndrome, different CVMDs 
often develop simultaneously, so that obese 
patients present with an increased risk of 
suffering also from type II diabetes and 
insulin-resistance, these being frequently 
associated with atherosclerosis and hyper-
tension, suggesting the sharing of similar 
pathogenic mechanisms.
AdAptive t cell immunity in cvmds
Chronic low-grade inflammation is a key 
feature of CVMDs. Macrophages and innate 
immunity have been classically implicated 
in the pathogenesis of atherosclerosis, and 
more recently of hypertension, as well as 
other metabolic disorders associated with 
cardiovascular disease such as obesity and 
type II diabetes (Hotamisligil, 2006; Rocha 
and Libby, 2009; Harrison et al., 2010; 
Matarese et al., 2010; Schiffrin, 2010; Baker 
et al., 2011; Donath and Shoelson, 2011; 
Hansson and Hermansson, 2011; Lahoute 
et al., 2011).
Evidence for the contribution of T cell-
mediated immunity to CVMDs has only 
recently emerged. T cells infiltrate athero-
sclerotic plaques, obese adipose tissue, pan-
creatic islets, and the perivascular fat and 
kidneys in hypertensive individuals. In these 
sites, proinflammatory immune responses 
mediated by CD4+ T-helper type 1 (TH1) 
and CD8+ cytotoxic T lymphocytes are pre-
ponderant over immunomodulatory (TH2) 
and immunosuppressive (Treg) immunity, 
and drive disease progression (Rocha and 
Libby, 2009; Baker et al., 2011). Interferon 
(IFN)-γ, the signature TH1 cytokine, is found 
in human atherosclerotic plaques and obese 
adipose tissue, where it exerts pathogenic 
effects by promoting the recruitment and 
activation of macrophages and the release 
of proinflammatory cytokines such as 
Tumor Necrosis Factor (TNF), all of which 
perpetuate the local inflammation (Gupta 
et al., 1997; Ranjbaran et al., 2007; Rocha 
and Libby, 2009; Hansson and Hermansson, 
2011). In contrast, Interleukin (IL)-4, the 
prototypical anti-inflammatory cytokine of 
the TH2 lineage, is not frequently observed 
in human plaques (Rocha and Libby, 2009; 
Hansson and Hermansson, 2011). TH1-
mediated proinflammatory mechanisms 
have also been involved in the pathogen-
esis of hypertension (Mahmoud et al., 2003; 
Shao et al., 2003; Seaberg et al., 2005; Guzik 
et al., 2007; Harrison et al., 2010; Schiffrin, 
2010). RAG1−/− mice, which lack both T and 
B cells, develop neither angiotensin II- nor 
deoxycorticosterone acetate (DOCA) salt-
induced hypertension, and adoptive transfer 
of T cells, but not B cells, restores the hyper-
tensive phenotype induced by these stimuli 
(Guzik et al., 2007). Immunosuppressive Treg 
lymphocytes appear to be reduced in num-
ber in human atherosclerotic plaques (de 
Boer et al., 2007; Lahoute et al., 2011) and in 
the adipose tissue of insulin-resistant obese 
mice (Feuerer et al., 2009; Matarese et al., 
2010). Blockade of IL-10 and Transforming 
Growth Factor (TGF)-β, the two cytokines 
responsible for most of the immunosup-
pressive effects mediated by Treg cells, 
accelerates lesion development (Lahoute 
et al., 2011). Adoptive transfer of Treg cells 
reduces atherosclerosis in Apo−/− mice (Ait-
Oufella et al., 2006; Lahoute et al., 2011) and 
insulin-resistance in obese mice (Feuerer 
et al., 2009; Matarese et al., 2010). How 
proinflammatory T cells accumulate in the 
inflamed sites is an open question.
the metAbolic mAchinery And t 
cell function
The regulation of energy metabolism 
is crucial to T cell-mediated immunity, 
including activation, proliferation, and 
differentiation toward effector versus 
regulatory T cells, and, as we discuss here, 
migration. Naïve T cells rely upon a cata-
bolic type of metabolism whereby ATP is 
mainly generated via oxidative phospho-
rylation (OXPHOS). This slow metabolism 
is sufficient to support their requirements 
for survival, maintain housekeeping func-
tions, such as ion transport and membrane 
integrity, and keep them away from engag-
ing into cell proliferation (Rathmell et al., 
2000; Frauwirth and Thompson, 2004). 
Upon TCR engagement by cognate antigen, 
T cells switch from catabolism to anabo-
lism, with phosphatidylinositol 3′-kinase 
(PI3K) leading to the activation of the 
serine-threonine kinase AKT. This step pro-
motes glucose metabolism by stimulating 
the localization of the glucose transporter 
Glut1 to the plasma membrane and the 
activity of hexokinase and phosphofruc-
tokinase, two   rate-limiting enzymes of the 
glycolytic pathway. Increased glycolytic flux 
enables activated T cells to generate ATP 
and, at the same time, efficiently utilize 
carbon sources in the form of amino acids 
and lipids for the biosynthesis of proteins 
and membranes necessary for the expan-
sion phase that characterizes the immune 
response. Downstream of TCR, AKT also 
controls the activation state of the mam-
malian target of rapamycin (mTOR), a 
sensor of nutritional and energetic status 
in cells that promotes protein synthesis. 
mTOR is a key   regulator of T cell differ-
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these receptors can influence both efficiency 
and topography of T cell trafficking. The 
metabolic machinery is also likely to directly 
affect and be affected by T cell migratory 
events, as T cells continuously recirculate 
between different microenvironments (e.g., 
blood, lymphoid tissues, and peripheral tis-
sues) in which they are exposed to differ-
ent nutrient availability and oxygen (O2) 
tension, and must adapt their metabolic 
pathways to effectively mediate immune 
responses. The direct effect of metabolism 
on the trafficking ability of T cells, however, 
has not been investigated.
Memory lymphocyte trafficking is regu-
lated by a number of complex mechanisms, 
which involve both pro-migratory and 
pro-static events. Following priming in the 
lymph nodes, T cells migrate to antigen-rich 
sites to exert their effector function. Effector 
T cells are retained in the tissue for a time 
sufficient to achieve effective immunity. 
Homeostatic mechanisms prescribe that 
long-lived memory T cells leave the tissue 
once the immune response is complete, and 
inflammation then subsides. A failure of T 
cells to be released from the tissue leads to 
persistent inflammation and progressive tis-
sue damage (Burman et al., 2005). T cells 
are exposed to different metabolic environ-
ments during these migratory events, which 
are likely to affect their motility and abil-
ity to respond to migratory cues from the 
in adipose tissue,  pancreatic β-cells,  arterial 
walls, and the central  nervous system (Yuan 
et al., 2001; Gareus et al., 2008; Baker et al., 
2011; Purkayastha et al., 2011).
An important role for NF-κB in the 
organization of energy metabolism net-
works in the cell through the control of the 
balance between the utilization of glycoly-
sis and OXPHOS has recently been dem-
onstrated. NF-κB acts as a physiological 
regulator of mitochondrial respiration and 
via this function suppresses the metabolic 
reprogramming to aerobic glycolysis in cells 
and prevents necrosis upon nutrient star-
vation. This metabolic function of NF-κB 
involves the p53-dependent upregulation 
of mitochondrial Synthesis of Cytochrome 
c Oxidase 2 (SCO2), a crucial component 
of the electron transfer chain Complex IV 
or Cytochrome c Oxidase, which increases 
OXPHOS and reduces glycolytic flux in cells 
(Mauro et al., 2011).
Due to its ability to control both inflam-
matory and metabolic responses, NF-κB 
represents a major target, in addition to 
the mTOR pathway, for the development 
of novel therapeutic strategies in CVMDs 
(Figure 1).
metAbolic stress And t cell 
migrAtion
The control of T cell migration by TCR 
engagement and co-stimuli (Mirenda 
et al., 2007; Jarmin et al., 2008) implies 
entiation toward proinflammatory subsets, 
and its inhibition with rapamycin promotes 
immunosuppression via the induction of 
anergic and Treg cells (Jones and Thompson, 
2007; Zheng et al., 2009; Peter et al., 2010; 
Powell and Delgoffe, 2010; Marelli-Berg 
et al., 2012; Mauro et al., 2012).
Indirect evidence suggests that metabolic 
status can influence T cell homing pat-
terns. Expression of the adhesion molecule 
CD62L (also known as L-selectin) and the 
chemokine receptors CC-chemokine recep-
tor 7 (CCR7) and sphingosine-1-phosphate 
receptor 1 (S1P1) on the surface of naïve T 
cells facilitates their trafficking to second-
ary lymphoid organs (SLOs). Upon TCR 
engagement, the PI3K-AKT-mTOR axis 
promotes the downregulation of CD62L, 
CCR7, and S1P1, and prompts effector T 
cells expressing adhesion molecules [such 
as VLA4 (very late antigen 4) and ligands for 
P-selectin and E-selectin] and chemokine 
receptors (such as CXCR3 and CCR5) to 
traffic to the sites of inflammation (Sinclair 
et al., 2008).
Upon resolution of the immune 
response, the number of antigen specific 
T cells contracts, as effector cells die and 
only the memory subset survives. This step 
is characterized by a metabolic transition 
from anabolism to catabolism, from high 
mTOR activity to low mTOR activity, and 
from effector to memory cells (Sinclair 
et al., 2008; Finlay and Cantrell, 2011). 
This transition is associated with the re-
expression of CD62L and CCR7, thus 
allowing the newly formed memory cells 
to continue surveillance by trafficking in 
and out of SLOs. Consistently, rapamycin-
mediated inhibition of mTOR causes effec-
tor T cells to re-express CD62L and CCR7, 
and home to SLOs where they are trapped 
away from the target sites in the periphery 
(Sinclair et al., 2008; Finlay and Cantrell, 
2011). Therefore, rapamycin can promote 
immunosuppression by redirecting effector 
T cells from peripheral tissues to SLOs.
nf-κb, inflAmmAtion, And cvmds
Nuclear Factor (NF)-κB is a family of 
transcription factors that promote immu-
nity by controlling the expression of genes 
involved in inflammation (Baker et al., 
2011). A number of recent studies have 
demonstrated a key role for NF-κB sign-
aling pathways in the development of 
inflammation-driven metabolic disorders 
Figure 1 | The control of inflammation and metabolism by NF-κB and its relevance to CVMDs. 
NF-κB transcription factors control several physiologic functions, including morphogenesis and 
differentiation, cell proliferation and apoptosis, immunity and inflammation. Recent work has shed light in 
the control of cell energy metabolism by NF-κB. By regulating both inflammatory and metabolic pathways, 
NF-κB has been involved in the pathogenesis of CVMDs, thereby opening the way to the identification of 
metabolic factors under NF-κB control as target for therapy.
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Investigation of the mechanisms for 
metabolic control of T cell trafficking rep-
resents a fascinating area – mostly unex-
plored – of research for the forthcoming 
years. The observations arising from such 
studies will provide key insights into both 
the physiology of T cell trafficking and the 
physiopathologic mechanisms of T cell 
infiltration in inflammatory sites, where 
T cells are retained and perpetuate the 
chronic inflammation that drives the dis-
ease progression. Importantly, while the 
antigen specificities promoting the activa-
tion of the adaptive immunity in humans 
are controversial, these diseases have been 
associated to non-antigen specific mecha-
nisms involving altered T cell migration 
patterns (Burman et al., 2005; Full and 
Monaco, 2011). We propose that altered 
metabolism can fuel chronic inflamma-
tion in an antigen-non-specific manner, 
i.e., that otherwise harmless immune 
responses might fail to resolve leading 
to chronic inflammation and bystander 
damage when they occur in a metaboli-
cally altered environment. Similar mecha-
nisms are likely to be important in other 
cardiovascular diseases (e.g., hyperten-
sion, stroke, heart transplantation, etc.) 
with a T cell-mediated inflammatory 
component. Additional associations are 
being drawn between CVMDs, such as 
obesity, and diseases that are less obviously 
linked to metabolic alterations, includ-
ing asthma, arthritis, lupus, Alzheimer, 
and several forms of cancer (Mathis and 
Shoelson, 2011; Gerriets and Rathmell, 
2012). Inflammation has been etiologi-
cally associated to the pathogenesis of each 
of these conditions, and the binomium 
metabolism-inflammation might provide 
new effective therapeutic protocols for a 
wide range of diseases that share similar 
pathogenic mechanisms.
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surrounding microenvironment. Thus, it is 
conceivable that altered migration might 
result from an altered metabolic microen-
vironment (blood, tissues, or the inflam-
matory milieu itself) and that this might in 
turn initiate or sustain chronic inflamma-
tion, as it happens in CVMDs. Specifically, 
metabolic alterations that characterize the 
metabolic syndrome, including nutrient 
excess, hyperglycemia and hyperlipidemia, 
might promote T cells infiltration of inflam-
matory sites by modifying their intracellular 
metabolism. Once inside the inflamed tis-
sue, T cells could become immobile due to 
a drop in O2 tension, nutrient availability, 
or pH that affects their metabolic status. 
The inability of differentiated T cells to exit 
inflamed tissues would favor the persistence 
of chronic inflammation.
concluding remArks
Immunosuppressive therapies have been 
proposed in CVMDs. TNF blockade reduced 
the incidence of cardiovascular events in 
patients with rheumatoid arthritis (RA), 
an autoimmune disease associated with a 
strong inflammatory component and with 
accelerated atherosclerosis (Jacobsson et al., 
2005; Greenberg et al., 2011). Sirolimus 
(rapamycin), an inhibitor of the mTOR 
approved for use in the prevention of trans-
plant rejection, is being tested in pre-clinical 
studies of cardiovascular disease in animal 
models and has been used with some suc-
cess in the clinic for the local treatment of 
restenosis (Adelman, 2010).
In addition to conventional immuno-
suppression, compounds targeting meta-
bolic pathways have been shown to exert 
anti-inflammatory properties. For instance, 
essential amino acid depletion has been 
shown to contribute to tolerance induc-
tion in experimental heart transplantation 
(Sucher et al., 2012). Similarly, n−3 poly-
unsaturated fatty acids (PUFAs) from fish 
oils, EPA, and DHA, popularly referred to 
as omega-3 fatty acids, with hypotriglyc-
eridemic, hypotensive, and antithrombotic 
properties, have been shown to inhibit 
inflammatory responses associated with 
alteration of lipid metabolism (Cottin et al., 
2011). The inhibition of immune-inflam-
mation by correcting altered metabolism 
is an attractive therapeutic strategy which 
would specifically target CVMDs with-
out the severe side-effects of conventional 
immunosuppression.
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